Audit: QRS - Gastrodin for Health & Longevity

Audit conducted on 12/09/2026 13:11 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: at-a-glance against Conclusion, protocol cells against Therapeutic Protocol, time cells against the Practical Considerations “Time to effect” bullet, benefit/risk tiers against the ER subsection headings, gates against Key Interactions & Contraindications, monitoring rows against the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No cautious ER phrasing is carried into the QRS in an altered form; the High risk tier, which the ER opens with “No risk reaches High”, is hidden rather than reworded.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute (pregnancy, under 18, Child-Pugh C, eGFR <30, injectable outside China); “Genuine short-term effects” mirrors the ER’s “real findings”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from Key Interactions & Contraindications; the Sedation time cell comes from the ER’s own “Time to effect” bullet, not from the Low risk tier.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, NCT identifiers, author names or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present; the ER’s “EASTERN protocol” attribution was dropped rather than replaced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, sceptical register (“Trial quality is low”, “rests on worms and cell cultures”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	States what is genuinely established and when it appears (“Real effects emerge within weeks”) alongside the limits.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells describe what trials and protocols used; no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence and qualitative items are phrased descriptively, e.g. “residual sedation after 10 a.m. signals too much or too late a dose”.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of recommend/advise/should in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names and mechanisms the ER itself uses; the lede is jargon-free.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, tier lists and monitoring cells are trimmed to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”; none found.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges, escalation cadence and split-dosing detail address an applying reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily blood-pressure logging, split three-times-daily dosing and a 12-week blood panel are carried without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; the sheet assumes self-directed measurement.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance flags that the longevity rationale is unsupported while the symptomatic effects are real — the distinction that matters to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” used in the title and lede; no occurrence of “anti-aging” in the file.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“Standard oral dose”, “Injectable form”, “hypersensitivity”, “adverse reactions”; no “pill”, “shot” or “taken by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers match the template byte-for-byte (lines 445, 491, 537, 567, 584, 608, 635, 639–641, 768).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; the only additions are the template’s repeatable marker_#_* (9 rows) and qualitative_item_# (6 items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Normalized diff against the template shows no change outside the variable spans; website="evidence_review", website="audit" and website="full_review" spans, CSS and footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the absent High risk tier is governed by item 13.5, which requires display:none rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard oral dose”, “Split versus single dose”, “Best time of day” and all six qualitative labels are verbatim ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring row labels match the ER biomarker column exactly; the three time-cell labels (“Headache frequency”, “Blood pressure”, “Sedation”) are taken word-for-word from the ER’s “Time to effect” bullet.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode scan for symbol-class characters returns none; the ER’s “⚠️ Conflicted” marker on the cardiac-surgery benefit was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Gate items, tier lists and monitoring “Why” cells are all single short phrases; example drug lists trimmed from four or five names to one or two.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, lede or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: gastrodin_2026-0912-0917_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0912-1258.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename gastrodin_2026-0912-0917_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys, including the appended git_user and git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Gastrodin for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Gastrodin for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/12/2026” from qrs_creation_date: 2026-0912-1258.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All five sentences map to the ER Conclusion: origin and licensing, the three real effects, the quality and single-country limit, the worms-and-cells longevity basis, and the weeks-not-years timeframe.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a separate ER Conclusion sentence; no synthesis beyond the ER.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“confusion after heart surgery” rather than delirium/cardiac surgery; no acronyms, no clinical-register words.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No mmHg figures, risk ratios or confidence intervals.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER’s “Populations who should avoid Gastrodin” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER bullets represented; the first is split into hypersensitivity-to-gastrodin and multi-drug-hypersensitivity, which the ER states as two conditions.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements, lines 570–579.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing clause stripped, e.g. “no human reproductive data and no reproductive toxicology study exist”, “aglycone clearance is hepatic and no dosing data exist”. No dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(Child-Pugh Class C)”, “(eGFR below 30 mL/min/1.73 m²) or dialysis”, “under 18”, “systolic persistently below 100 mmHg” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets contain no ranking notation; thresholds are written out in words (“eGFR below 30 mL/min/1.73 m²”).
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Twelve items matching the ER’s twelve interaction bullets, in the ER’s order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Twelve <li> elements, lines 587–598.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All “Caution —” / “Monitor —” clauses and mitigations stripped; the only retained tail is “no interaction” on the analgesics item, which is the key fact itself, not an elaboration.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every class keeps one or two named examples (amlodipine/losartan, zolpidem/diazepam, ramelteon, valproate/phenytoin, fluoxetine/sertraline, digoxin/dabigatran, diphenhydramine, ibuprofen, beetroot nitrate, valerian/L-Theanine, N-acetylcysteine); none dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheses are plain comma-separated drug lists with no ranking symbols.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to bullets in the ER Therapeutic Protocol section.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dose splitting and timing — the three bullets that determine what is actually taken and when; the remaining ER bullets are modifiers or non-self-administrable alternatives.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“300–600 mg daily” spans the ER’s 600 mg EASTERN dose tapered to 300 mg; “Split dosing” and “Evening-weighted” carry the ER’s half-life and MT₁/GABA rationale.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Headache frequency, blood pressure and sedation — exactly the three named in the ER’s “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Headache burden and blood pressure are both High-tier benefits, in the ER’s own order; sedation, which is not a graded benefit, comes last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“4–12 weeks”, “2–4 weeks” and “Same night” with subs quoting the ER bullet nearly verbatim.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items correspond to the ten ER benefit subsection headings, in their ER tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 539, 546, 549, 555).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Mechanistic tails stripped, e.g. “Lifespan Extension Through DAF-16/FOXO Signalling” → “Lifespan extension”; “Sleep Promotion via Melatonin MT₁ Receptor Activation” → “sleep promotion”.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses, RRs, mean differences or confidence intervals appear in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no benefit span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven items correspond to ER risk subsection headings in their ER tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 610, 613, 619, 624).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only, semicolon-separated; no 85.5%/74.4% figures, no Zheng et al. attribution.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses or frequency figures in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”; the risks_high span carries style="display: none" at line 610 with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows come from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present with matching targets: seated blood pressure, eGFR, serum creatinine, ALT, AST, eosinophil count, hs-CRP, fasting glucose, resting heart rate.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 758 reproduces the ER’s front-loaded schedule: twice daily for two weeks, then weekly; weekly diary; panel at baseline and 12 weeks, then every 6–12 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s qualitative-marker bullet list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six present: headache days, dizziness episodes, sleep onset and night wakings, morning alertness, cognitive clarity, mood and stress reactivity.

Issues 12/09/2026 13:11

Pass rate 100.00%. No issues found.

Issues 12/09/2026 13:00

1. 4.5 — Content overflows one A4 page: The sheet renders at roughly twice the one-page budget; the Key Interactions gate (lines 588–611) carries twelve items each with a four- to five-drug parenthetical, and the protocol subs, contraindication items, monitoring cadence and qualitative items all run at full ER length rather than condensed.

Fixes 12/09/2026 13:00

1. 4.5 — Key Interactions trimmed to fit: Shortened every example-drug parenthetical in the twelve [caution_items] to one or two representatives (e.g. “Antihypertensive drugs (amlodipine, lisinopril, losartan, hydrochlorothiazide)” to “Antihypertensive drugs (amlodipine, losartan)”), cutting the gate from about 25 wrapped lines to 17 while keeping every interaction and its drug class.
2. 4.5 — Contraindication items condensed: Trimmed redundant wording in three [stop_items] (“to gastrodin, to Gastrodia elata or to injectable gastrodin excipients” to “to gastrodin, Gastrodia elata or injectable excipients”; “systolic blood pressure persistently” to “systolic persistently”; “The injectable form” to “Injectable form”), preserving all thresholds and severity classes.
3. 4.5 — Protocol sub-text shortened: Reworded all three [action_#_sub] cells to drop one wrapped line each, keeping the doses, the four-to-six-hour half-life and the MT₁/GABA rationale intact.
4. 4.5 — Qualitative items and cadence condensed: Tightened the tails of three qualitative markers and the [monitoring_cadence] sentence without changing any interval, retaining all six ER markers and the full baseline/12-week/6-to-12-month schedule.